Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. - Wikidata - awgldk - TriplyDB

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

http://www.wikidata.org/entity/Q42045560

about

Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma A periodic table for cancer The significance of genetics for cholangiocarcinoma development Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies What are the precursor and early lesions of peripheral intrahepatic cholangiocarcinoma?Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.Pathogenesis, diagnosis, and management of cholangiocarcinoma New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.Genetic study of congenital bile-duct dilatation identifies de novo and inherited variants in functionally related genes GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Characterizing the activation of the Wnt signaling pathway in hilar cholangiocarcinoma using a tissue microarray approach.Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.Clinical analysis of cholangiocarcinoma patients receiving adjuvant radiotherapy.Intrahepatic cholangiocarcinoma: current perspectives.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Surgical management of proximal bile duct cancers.Genomic and transcriptional alterations of cholangiocarcinoma.Molecular pathogenesis of intrahepatic cholangiocarcinoma.Cholangiocarcinoma: from molecular biology to treatment.New Horizons for Precision Medicine in Biliary Tract Cancers.Emerging molecular targets and therapy for cholangiocarcinoma.Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion Inhibitory effects of resveratrol on hepatitis B virus X-protein (HBx)-induced hepatocellular carcinoma (HCC).An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.IDH mutations in liver cell plasticity and biliary cancer.Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population

P2860

Q26751655-EAFE3BF9-960F-4F5B-A05D-251EAC944CC6 Q26784091-7E43C368-EA0E-4C93-A02F-00F7F2CD2DA0 Q26858878-1BD2C047-33C0-4CF7-AC1F-57A0B0CCF67B Q26865749-9BFFEE8D-183A-4ABE-AB3E-2DCAE79EF6EC Q27002547-5ED9BAF0-97DA-44B1-A6CD-8FB98E86D477 Q33594336-A00FC7E0-F12E-485C-BF31-3FC5307549BB Q33757122-123A16AF-CA44-4C0E-8CA4-D558DFCA4CA6 Q33763540-EF6B37D8-5A05-474E-8A53-0A49FCE615B1 Q33779691-8C536C06-F972-47E5-AA96-74EB76D425DE Q33957174-7B872884-274A-43AB-87B6-B63738A3A4E1 Q34148155-05C03C4B-91D8-4A78-A363-393B715767B7 Q34499647-5972E5A1-22AB-4F34-9E0B-4F05A53F3ED2 Q34656747-C27F1EF7-BD8C-4D84-B81D-A6A112D30D3C Q35100996-0AF94245-E752-4EE2-9940-ACF19ED91BA8 Q35820533-B39711BE-3240-428B-9C35-92A7E0ACEECD Q35842729-227CEB40-30BF-4657-87C9-FF321287CAE1 Q35949450-328BEEA6-98EB-4DBA-B0AB-8C6A3BFC0418 Q36220868-FFDF953C-68C8-4F8A-922F-783CDBFB76EE Q36288756-15177B1C-0C99-49AB-B3F5-4BDDB55C97C3 Q36398735-9D51CD3E-44A6-4642-B186-12CF7F6F5ADC Q36707594-7974145C-A5FF-45DC-B951-2A7F70627D78 Q37190258-B51DBD0C-71FD-4BC3-BC06-E4CFB4A48D86 Q37353061-23C0D69E-BB18-4D6E-B37A-C3D9B9E80F51 Q37582417-12BD9541-F091-4DAB-9FC1-F5EE9E072438 Q37669928-E52B90FE-C873-4FDE-A324-FB69E77785A3 Q37719383-139A1D2E-ACDF-46F0-8CDD-C36F9A6B5B77 Q37990746-47F8E2C7-48D7-4EFC-BF2B-C6BA5FAC847C Q38188515-34E7A867-0BEB-40F4-A21E-492E5A8729FF Q38244965-B5D7CC47-D662-4A4A-B46E-AFD3DD739121 Q38597008-1AEE8F2F-7382-43AD-B253-788223F75F1A Q38619219-6BA69457-AF4C-4982-88DF-92DCDFF22091 Q38642455-6AEB0ACA-C6BF-4F47-BC75-9208F1CFB588 Q38714341-A320FA2A-0173-4469-BD4A-E3606224BF76 Q38965092-C5220F7D-16A7-4AF7-A25C-1606685D90B0 Q39318012-485A31CC-68F3-4D2A-A299-991193DD2CFC Q39769621-B6E2C2DF-647C-4D94-BB63-D4D8FE642BB0 Q40254603-D1B0F66D-2DC4-443D-9ECC-CCE8E9FA05F2 Q40324354-59D895D1-FF86-4848-9BF5-E3E936D52071 Q42594611-E100BFE0-9D52-4B1E-83B2-61109258C758 Q42687892-5C1391EE-819F-4DC9-87B1-A27E3A452609

P2860

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

http://www.wikidata.org/entity/Q42045560

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Kras

@nl

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

@en

type

label

Kras

@nl

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

@en

prefLabel

Kras

@nl

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

@en

P1433

Q42045560-685AF09C-2018-4791-8BB3-EDD4C56E9DC9

P1476

Q42045560-36767023-0AA8-436C-B32D-E82B12B080EE

P2093

Q42045560-21785AE8-376C-4A63-AE84-843D23136C53

Q42045560-22B3ACED-0321-4BD4-872B-DBBC5A989D9E

Q42045560-320518C0-D6ED-44B0-81AC-21AB2419C3A6

Q42045560-9AADF69E-C985-42F0-ABBC-9D475F319498

Q42045560-B815F03A-B9B3-4D54-8B33-103EE8642FD2

Q42045560-C0801F0B-FBEF-4A7F-ACFD-91C305BE60D8

Q42045560-C8F351EC-32C6-4578-A345-B363E895F2D9

Q42045560-CCF94552-B2DD-492B-AEAD-CA54D2846973

Q42045560-DBAB0721-993B-4558-BBF5-FF59EB92A4D4

Q42045560-DFC88981-9809-492A-9EF8-3EBA9601C980

P2860

Q42045560-019B681F-F037-46AE-992E-7DDE2A685211

Q42045560-037280FB-270E-4AAD-A461-ED35E8A2BBF0

Q42045560-14300419-F860-44C5-AFBD-6294F3F64D32

Q42045560-1506F99B-70F8-40A4-911E-B45F6645C09F

Q42045560-1E4A3454-35A8-4D8F-A4ED-632FB00BBEB7

Q42045560-22521CF8-9C5E-456F-BCEA-E61402CEBD60

Q42045560-2271F2B5-5199-4265-9BCB-FC7E84A94509

Q42045560-227DB3F9-74A9-4BAC-848E-615702D9F6B4

Q42045560-26199343-B79B-4178-9695-640AF29BE711

Q42045560-2F3C16F5-6AFD-4E34-BF5C-BE2D4822FC13

P304

Q42045560-40083760-E6EB-459D-83F8-156B1A688321

P31

Q42045560-35B74B34-5DAA-4DFB-A7C2-1820E98BD894

P356

Q42045560-09351B3F-1F26-43F4-ABD2-DBFF8678FA95

P407

Q42045560-7F7F304C-76E3-4AFF-815A-45BD3761AF65

P433

Q42045560-7BC053E1-C450-4D17-AB3B-B7A5DC7EF122

P478

Q42045560-FFBB7AE3-5345-4740-8CB5-5DD2006FF645

P50

Q42045560-3850F48C-9DB8-40A4-9B84-47A8F5E90BF2

P577

Q42045560-E543F17C-4D3B-4A45-B089-8126B3960C95

P698

Q42045560-2625D27F-0377-4113-B1A0-2707BC28EA3E

P921

Q42045560-4AD7E06B-FA6C-4193-96C6-641E2CE592E7

P932

Q42045560-72FC248C-4D49-4595-B6B2-BC6371A7AD7A

P356

0008-5472.CAN-11-3596

P1433

Cancer Research

P1476

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Aram F Hezel

http://www.w3.org/2001/XMLSchema#string

Christa L Whitney-Miller

http://www.w3.org/2001/XMLSchema#string

Hartmut Land

http://www.w3.org/2001/XMLSchema#string

Jing Li Huang

http://www.w3.org/2001/XMLSchema#string

Michael R O'Dell

http://www.w3.org/2001/XMLSchema#string

Nabeel Bardeesy

http://www.w3.org/2001/XMLSchema#string

Paul Rothberg

http://www.w3.org/2001/XMLSchema#string

Randall M Rossi

http://www.w3.org/2001/XMLSchema#string

Valerie Grose

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Principles of tumor suppression

Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride

Pancreatic cancers require autophagy for tumor growth

p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma.

Evidence for the neoplastic transformation of Von-Meyenburg complexes.

Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation

P304

1557-1567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-3596

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Nabeel Bardeesy

P577

2012-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22266220

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3306549

http://www.w3.org/2001/XMLSchema#string